Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF
NCT02256683 · Johannes Gutenberg University Mainz · PHASE2 · terminated · last registry update 2019-07-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recruiting problems” | – | Registry record, Johannes Gutenberg University Mainz |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-07-13Results posted on the registry: Yale University, Enoxaparin (NCT03003390)
- 2020-07-13Also stopped (terminated): Yale University, Enoxaparin (NCT03003390)
- 2020-07-07Phase 3 first posted: Suzhou Zelgen Biopharmaceuticals Co.,Ltd, recombinant human Thrombin(CHO cell) + placebo (NCT04459871)
- 2020-07-07Results posted on the registry: Boehringer Ingelheim, dabigatran etexilate + standard of care (NCT01895777)
- 2020-06-16Results posted on the registry: PTC Therapeutics, Ataluren (NCT00947193)
- 2020-06-16Also stopped (terminated): PTC Therapeutics, Ataluren (NCT00947193)
- 2020-06-04Results posted on the registry: Boehringer Ingelheim, dabigatran etexilate (NCT02197416)
- 2020-05-19Results posted on the registry: Pfizer, SPK-9001 (NCT02484092)
- 2020-04-14Results posted on the registry: Boehringer Ingelheim, Idarucizumab (NCT02815670)
- 2020-02-26Phase 3 first posted: Population Health Research Institute, DOAC + VKA (NCT04284839)
- 2019-08-05Phase 3 first posted: Icahn School of Medicine at Mount Sinai, Antiplatelet-only strategy + Oral Anticoagulant plus background antiplatelet therapy (NCT04045665)
- 2019-06-25Phase 3 first posted: Imperial College London, Apixaban Oral Tablet + Dabigatran (NCT03996772)
- 2019-05-23Phase 3 first posted: University of Zurich, Dabigatran + Apixaban (NCT03961334)
- 2019-05-06Phase 3 first posted: Pfizer, PF-06741086 (NCT03938792)
- 2019-04-11Results posted on the registry: Medexus Pharma, Inc., IB1001 (NCT01271868)
- 2019-03-04Phase 3 first posted: Pfizer, PF-06838435/ fidanacogene elaparvovec (NCT03861273)
- 2019-02-26Phase 3 first posted: Medexus Pharma, Inc., APVO101 (NCT03855280)
- 2019-01-18Phase 3 first posted: Aspen Global Incorporated, Danaparoid Sodium + Argatroban (NCT03809481)
- 2018-11-23Results posted on the registry: Bioverativ Therapeutics Inc., rFIXFc (NCT01425723)
- 2018-11-08Phase 3 first posted: Washington University School of Medicine, Argatroban + Eptifibatide (NCT03735979)
- 2018-10-11Phase 3 first posted: Massachusetts General Hospital, Rivaroxaban + Warfarin (NCT03702582)
- 2018-09-10Results posted on the registry: Baxalta now part of Shire, BAX 326 (Recombinant factor IX) (NCT01286779)
- 2018-09-10Results posted on the registry: Medexus Pharma, Inc., IB1001 + nonacog alfa (NCT00768287)
- 2018-08-16Phase 3 first posted: Centre Hospitalier Universitaire de Nīmes, Blood test (NCT03634124)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision